<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="39234">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02595632</url>
  </required_header>
  <id_info>
    <org_study_id>KEK-ZH-Nr. 2015-0187</org_study_id>
    <nct_id>NCT02595632</nct_id>
  </id_info>
  <brief_title>Breath Analysis in Healthy Controls</brief_title>
  <official_title>Exhaled Breath Analysis by Secondary Electrospray Ionization (SESI-MS) in Healthy Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss Federal Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to detect a specific profile of breath in healthy subjects by
      an untargeted metabolomic study using exhaled breath analysis by mass spectrometry.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome will be the mass spectrometric exhaled breath pattern of healthy subjects.</measure>
    <time_frame>1 day, single measurement, no follow up</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Exhaled Breath</condition>
  <condition>Mass Spectrometry</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <description>Healthy subjects with no apparent lung disease and normal lung function testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <arm_group_label>Healthy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy subjects will be included according to the predefined inclusion and exclusion
        criteria. They will be recruited from the general population by printed flyers, newspaper
        advertisements and personal communication.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Normal spirometry (forced expiratory volume in 1 second (FEV1) &gt; 80%, forced vital
             capacity (FVC) &gt; 80%, FEV1/FVC &gt; 70%.).

          2. Age between 18 and 90 years at study entry.

        Exclusion Criteria:

          1. Presence of an active malignancy.

          2. Presence of any lung disease (e.g. asthma, chronic obstructive pulmonary disease
             (COPD), sarcoidosis)

          3. Acute inflammatory disease (e.g. common cold) within the last 6 weeks.

          4. Acute or chronic hepatic disease.

          5. Renal failure or renal replacement therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Malcolm Kohler, MD</last_name>
    <phone>+41 44 255 38 28</phone>
    <email>malcolm.kohler@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yvonne Nussbaumer, MD</last_name>
    <phone>+41 44 255 38 28</phone>
    <email>yvonne.nussbaumer@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zurich, Pulmonary Division</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malcolm Kohler, MD</last_name>
      <phone>+41 44 255 38 28</phone>
      <email>malcolm.kohler@usz.ch</email>
    </contact>
    <contact_backup>
      <last_name>Yvonne Nussbaumer, MD</last_name>
      <phone>+41 44 255 38 28</phone>
      <email>yvonne.nussbaumer@usz.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Malcolm Kohler, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Renato Zenobi, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 17, 2016</lastchanged_date>
  <firstreceived_date>November 2, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
